Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)

被引:11
|
作者
Batteux, Benjamin [1 ,2 ,3 ,4 ]
Bennis, Youssef [1 ,3 ]
Bodeau, Sandra [1 ,3 ]
Masmoudi, Kamel [1 ]
Hurtel-Lemaire, Anne-Sophie [1 ]
Kamel, Said [3 ,5 ]
Gras-Champel, Valerie [1 ,3 ]
Liabeuf, Sophie [1 ,3 ]
机构
[1] Amiens Univ, Dept Pharmacol, Med Ctr, F-80054 Amiens, France
[2] St Quentin Med Ctr, Dept Rheumatol, F-02321 St Quentin en Yvelines, France
[3] Jules Verne Univ Picardie, MP3CV Lab, EA7517, F-80054 Amiens, France
[4] Amiens Picardie Univ, RECIF, Med Ctr, F-80054 Amiens, France
[5] Amiens Univ, Biochem Lab, Med Ctr, F-80000 Amiens, France
关键词
Osteoporosis; Drug; Pharmacology; Pharmacoepidemiology; Pharmacovigilance; BONE-MINERAL DENSITY; RHEUMATOID-ARTHRITIS PATIENTS; LOW-DOSE METHOTREXATE; POSTMENOPAUSAL WOMEN; FRACTURE RISK; VITAMIN-A; PSYCHOTROPIC MEDICATIONS; INADEQUATE RESPONSE; MULTIPLE-SCLEROSIS; SIGNAL GENERATION;
D O I
10.1016/j.bone.2021.116137
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Bone remodeling is a complex process, and many conditions (including drug exposure) lead to osteoporosis. Here, we sought to detect new disproportionality signals for drugs associated with osteoporosis. Methods: We performed a disproportionality analysis of the World Health Organization's VigiBase (R) pharmacovigilance database through April 12, 2020. The frequency of reports on osteoporosis for all identified drug classes was compared with that for all other drugs and quoted as the reporting odds ratio (ROR) [95% confidence interval (CI)]. Results: Of the 7,594,968 cases spontaneously recorded to VigiBase (R), 4758 concerned osteoporosis. New disproportionality signals with a pharmacologically plausible mechanism were found for drugs used in neurology (levodopa (ROR [95%CI]: 10.18 [4.33-25.10]), selective serotonin agonists (4.22 [2.34-7.00]) and memantine (4.10 [1.56-8.93])), hematology (romiplostim (4.93 [1.15-21.10])), pulmonology (macitentan (3.02 [1.84-4.90])), ophthalmology (ranibizumab (3.31 [1.00-10.51])) and rheumatology (tofacitinib (3.65 [3.00-4.40])). The robustness of these new results is supported by the significant RORs for the vast majority of drugs already known to induce osteoporosis and/or increase the fracture risk, namely glucocorticoids, gonadotropin-releasing hormone analogs, anti-aromatases, androgen receptor blockers, thyroid hormones, proton pump inhibitors, thiazolidinediones, vitamin K antagonists, loop diuretics, protease inhibitors, nucleoside and nucleotide reverse transcriptase inhibitors, and enzyme-inducing antiepileptics including barbiturates and derivatives, hydantoin derivatives, carboxamide derivatives and fatty acid derivatives. Conclusion: We established up a comprehensive list of drugs potentially associated with osteoporosis and highlighted those with pharmacologically plausible mechanisms leading to bone fragility. Our results might pave the way for additional exploration of these mechanisms.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Respiratory infections in patients receiving Immune Checkpoint Inhibitors using the World Health Organization pharmacovigilance database- VigiBase
    Maitre, Thomas
    Ferry, Virginie
    Bihan, Kevin
    Canellas, Anthony
    Godet, Cendrine
    Cadranel, Jacques
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [22] Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization’s database
    Giulia Bonaldo
    Alberto Vaccheri
    Mauro Melis
    Domenico Motola
    Journal of Thrombosis and Thrombolysis, 2020, 50 : 763 - 771
  • [23] Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization's database
    Bonaldo, Giulia
    Vaccheri, Alberto
    Melis, Mauro
    Motola, Domenico
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 50 (04) : 763 - 771
  • [24] Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database
    Montastruc, Jean-Louis
    Lafaurie, Margaux
    de Canecaude, Claire
    Durrieu, Genevieve
    Sommet, Agnes
    Montastruc, Francois
    Bagheri, Haleh
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (11) : 4334 - 4340
  • [25] A Pharmacovigilance Approach for Post-Marketing in Japan Using the Japanese Adverse Drug Event Report (JADER) Database and Association Analysis
    Fujiwara, Masakazu
    Kawasaki, Yohei
    Yamada, Hiroshi
    PLOS ONE, 2016, 11 (04):
  • [26] Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database
    Chen, Xiao
    Wei, Lianhui
    Chi, Lijie
    Guo, Xiaojing
    Chen, Chenxin
    Guo, Zhijian
    Liang, Jizhou
    Zheng, Yi
    He, Jia
    Ye, Xiaofei
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (05) : 2180 - 2189
  • [27] Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
    Xing, Xiaoxuan
    Zhang, Xiaotong
    Wang, Ke
    Wang, Zhizhou
    Feng, Yingnan
    Li, Xiaoxi
    Hua, Yiming
    Zhang, Lan
    Dong, Xianzhe
    ALZHEIMERS RESEARCH & THERAPY, 2025, 17 (01)
  • [28] Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database
    Lee S. Nguyen
    Leslie T. Cooper
    Mathieu Kerneis
    Christian Funck-Brentano
    Johanne Silvain
    Nicolas Brechot
    Guillaume Hekimian
    Enrico Ammirati
    Badr Ben M’Barek
    Alban Redheuil
    Estelle Gandjbakhch
    Kevin Bihan
    Bénédicte Lebrun-Vignes
    Stephane Ederhy
    Charles Dolladille
    Javid J. Moslehi
    Joe-Elie Salem
    Nature Communications, 13
  • [29] Fetal adverse drug reactions with biologic Disease Modifying Anti-Rheumatic Drugs used during pregnancy: Insights from a World Health Organization pharmacovigilance database study (VigiBase®)
    Dernoncourt, A.
    Liabeuf, S.
    Bennis, Y.
    Masmoudi, K.
    Gras-Champel, V.
    Batteux, B.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 32 - 32
  • [30] Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database
    Nguyen, Lee S.
    Cooper, Leslie T.
    Kerneis, Mathieu
    Funck-Brentano, Christian
    Silvain, Johanne
    Brechot, Nicolas
    Hekimian, Guillaume
    Ammirati, Enrico
    Ben M'Barek, Badr
    Redheuil, Alban
    Gandjbakhch, Estelle
    Bihan, Kevin
    Lebrun-Vignes, Benedicte
    Ederhy, Stephane
    Dolladille, Charles
    Moslehi, Javid J.
    Salem, Joe-Elie
    NATURE COMMUNICATIONS, 2022, 13 (01)